Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors.
Nanographene oxide (NGO) is a novel nano-wall material that tracks to tumors in vivo, and which, as a consequence of its large surface area, has the capacity to carry a large payload. This study explores the use of anti-HER2 antibody (trastuzumab)-conjugated NGO, radiolabeled with (111)In-benzyl-die...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2013
|
| _version_ | 1797093448452407296 |
|---|---|
| author | Cornelissen, B Able, S Kersemans, B Waghorn, P Myhra, S Jurkshat, K Crossley, A Vallis, K |
| author_facet | Cornelissen, B Able, S Kersemans, B Waghorn, P Myhra, S Jurkshat, K Crossley, A Vallis, K |
| author_sort | Cornelissen, B |
| collection | OXFORD |
| description | Nanographene oxide (NGO) is a novel nano-wall material that tracks to tumors in vivo, and which, as a consequence of its large surface area, has the capacity to carry a large payload. This study explores the use of anti-HER2 antibody (trastuzumab)-conjugated NGO, radiolabeled with (111)In-benzyl-diethylenetriaminepentaacetic acid (BnDTPA) via ππ-stacking, for functional imaging. In two HER2-overexpressing murine models of human breast cancer, high tumor-to-muscle ratio was achieved, resulting in clear visualization of tumor using single-photon emission computed tomography (SPECT). In the BALB/neuT model and in BALB/c nu/nu mice bearing 231/H2N xenografts, tumor accumulation amounted to 12.7 ± 0.67 and 15.0 ± 3.7% of the injected dose/g (%ID/g) of tumor tissue at 72 h, with tumor-to-muscle ratios of 35:1 and 7:1, respectively. Radiolabeled NGO-trastuzumab conjugates demonstrated superior pharmacokinetics compared to radiolabeled trastuzumab without NGO, with more rapid clearance from the circulation. The use of NGO as a scaffold to build radiolabeled nano-immunoconstructs holds promise for molecular imaging of tumors. |
| first_indexed | 2024-03-07T04:00:33Z |
| format | Journal article |
| id | oxford-uuid:c46f0f25-8e08-4ee4-9ff2-d19ceefab613 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:00:33Z |
| publishDate | 2013 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:c46f0f25-8e08-4ee4-9ff2-d19ceefab6132022-03-27T06:23:21ZNanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c46f0f25-8e08-4ee4-9ff2-d19ceefab613EnglishSymplectic Elements at OxfordElsevier2013Cornelissen, BAble, SKersemans, BWaghorn, PMyhra, SJurkshat, KCrossley, AVallis, KNanographene oxide (NGO) is a novel nano-wall material that tracks to tumors in vivo, and which, as a consequence of its large surface area, has the capacity to carry a large payload. This study explores the use of anti-HER2 antibody (trastuzumab)-conjugated NGO, radiolabeled with (111)In-benzyl-diethylenetriaminepentaacetic acid (BnDTPA) via ππ-stacking, for functional imaging. In two HER2-overexpressing murine models of human breast cancer, high tumor-to-muscle ratio was achieved, resulting in clear visualization of tumor using single-photon emission computed tomography (SPECT). In the BALB/neuT model and in BALB/c nu/nu mice bearing 231/H2N xenografts, tumor accumulation amounted to 12.7 ± 0.67 and 15.0 ± 3.7% of the injected dose/g (%ID/g) of tumor tissue at 72 h, with tumor-to-muscle ratios of 35:1 and 7:1, respectively. Radiolabeled NGO-trastuzumab conjugates demonstrated superior pharmacokinetics compared to radiolabeled trastuzumab without NGO, with more rapid clearance from the circulation. The use of NGO as a scaffold to build radiolabeled nano-immunoconstructs holds promise for molecular imaging of tumors. |
| spellingShingle | Cornelissen, B Able, S Kersemans, B Waghorn, P Myhra, S Jurkshat, K Crossley, A Vallis, K Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. |
| title | Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. |
| title_full | Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. |
| title_fullStr | Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. |
| title_full_unstemmed | Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. |
| title_short | Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. |
| title_sort | nanographene oxide based radioimmunoconstructs for in vivo targeting and spect imaging of her2 positive tumors |
| work_keys_str_mv | AT cornelissenb nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors AT ables nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors AT kersemansb nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors AT waghornp nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors AT myhras nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors AT jurkshatk nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors AT crossleya nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors AT vallisk nanographeneoxidebasedradioimmunoconstructsforinvivotargetingandspectimagingofher2positivetumors |